DOD Biotech Public Company Limited reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported sales was THB 175.81 million compared to THB 133.66 million a year ago. Revenue was THB 191.15 million compared to THB 136.81 million a year ago. Net income was THB 5.31 million compared to net loss of THB 25.72 million a year ago. Basic earnings per share from continuing operations was THB 0.018 compared to THB 0.011 a year ago. Diluted earnings per share from continuing operations was THB 0.018 compared to THB 0.011 a year ago. Basic earnings per share was THB 0.012 compared to basic loss per share of THB 0.063 a year ago. Diluted earnings per share was THB 0.012 compared to diluted loss per share of THB 0.063 a year ago.
For the six months, sales was THB 293.22 million compared to THB 294.49 million a year ago. Revenue was THB 313.63 million compared to THB 298.19 million a year ago. Net loss was THB 12.12 million compared to THB 26.43 million a year ago. Basic loss per share from continuing operations was THB 0.014 compared to basic earnings per share from continuing operations of THB 0.023 a year ago. Diluted loss per share from continuing operations was THB 0.014 compared to diluted earnings per share from continuing operations of THB 0.023 a year ago. Basic loss per share was THB 0.029 compared to THB 0.064 a year ago. Diluted loss per share was THB 0.029 compared to THB 0.064 a year ago.